A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Study Director
- Telefonnummer: 949-418-1801
Studienorte
-
-
Maryland
-
Pikesville, Maryland, Vereinigte Staaten, 21208
- Study Site
-
-
Massachusetts
-
Brookline, Massachusetts, Vereinigte Staaten, 02445
- Study Site
-
Fall River, Massachusetts, Vereinigte Staaten, 02723
- Study Site
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55402
- Study Site
-
-
New Jersey
-
Marlboro, New Jersey, Vereinigte Staaten, 07746
- Study Site
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12205
- Study Site
-
Binghamton, New York, Vereinigte Staaten, 13905
- Study Site
-
Buffalo, New York, Vereinigte Staaten, 14217
- Study Site
-
East Syracuse, New York, Vereinigte Staaten, 13057
- Study Site
-
Middletown, New York, Vereinigte Staaten, 10941
- Study Site
-
New York, New York, Vereinigte Staaten, 10036
- Study Site
-
Rochester, New York, Vereinigte Staaten, 14609
- Study Site
-
-
Pennsylvania
-
Erie, Pennsylvania, Vereinigte Staaten, 16508
- Study Site
-
Hatboro, Pennsylvania, Vereinigte Staaten, 19040
- Study Site
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Study Site
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15236
- Study Site
-
Pottstown, Pennsylvania, Vereinigte Staaten, 19464
- Study Site
-
West Chester, Pennsylvania, Vereinigte Staaten, 19380
- Study Site
-
-
Rhode Island
-
Warwick, Rhode Island, Vereinigte Staaten, 02886
- Study Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Overtly healthy adult participants aged 18 to 70 years
- Able to provide written informed consent
- Willing and able to comply with study procedures
- At high risk of exposure to ticks
- Contraceptive use by men and women consistent with local regulations
Exclusion Criteria:
- Prior exposure to TP05 or any isooxazoline in the last 12 months
- Known hypersensitivity to TP05 or related compounds
- Clinically significant medical conditions that may interfere with study participation
- Use of investigational products within 30 days prior to screening.
- Received previous vaccination against Lyme borreliosis, including investigational vaccines intended to prevent Lyme borreliosis
- Receiving long-term antibiotic therapy
- Received active or passive immunization within 4 weeks prior to Day
- Pregnant or breastfeeding individuals
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: TP-05 (lotilaner) High Dose
Oral Tablet
|
TP05 administered orally at the protocol-defined preventative dose.
|
|
Placebo-Komparator: Placebo
Oral Tablet
|
Matching placebo administered orally according to the same dosing schedule as TP05.
|
|
Aktiver Komparator: TP-05 (lotilaner) Low Dose
Oral Tablet
|
TP05 administered orally at the protocol-defined preventative dose.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The Incidence of Treatment Emergent Adverse Events From Baseline
Zeitfenster: From day 1 through the end of study follow-up, an average of 15 months.
|
Safety and tolerability will be evaluated by incidence rate of treatment emergent adverse events from baseline.
|
From day 1 through the end of study follow-up, an average of 15 months.
|
|
Clinically Significant Changes From Baseline Chemistry Laboratory Tests
Zeitfenster: From day 1 through the end of study follow up, an average of 15 months.
|
Number of participants with clinically significant changes in clinical laboratory tests
|
From day 1 through the end of study follow up, an average of 15 months.
|
|
Clinically Significant Changes From Baseline Hematology Laboratory Tests
Zeitfenster: From day 1 through the end of study follow up, an average of 15 months.
|
Number of participants with clinically significant changes in clinical laboratory tests.
|
From day 1 through the end of study follow up, an average of 15 months.
|
|
Clinically Significant Changes From Baseline Vital Signs
Zeitfenster: From day 1 through the end of study follow up, an average of 15 months.
|
Number of participants with clinically significant changes in vital signs.
|
From day 1 through the end of study follow up, an average of 15 months.
|
|
Clinically Significant Changes From Baseline Electrocardiograms (ECGs)
Zeitfenster: From day 1 through the end of study follow up, an average of 15 months.
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in mean ventricular rate [beats/min].
|
From day 1 through the end of study follow up, an average of 15 months.
|
|
Clinically Significant Changes From Baseline Electrocardiograms (ECGs) Measures
Zeitfenster: From day 1 through the end of study follow up, an average of 15 months.
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in pulse rate [msec].
|
From day 1 through the end of study follow up, an average of 15 months.
|
|
Clinically Significant Changes From Baseline QTC Interval
Zeitfenster: From day 1 through the end of study follow up, an average of 15 months.
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in QTC interval
|
From day 1 through the end of study follow up, an average of 15 months.
|
|
Clinically Significant Changes From Baseline QRS Interval
Zeitfenster: From day 1 through the end of study follow up, an average of 15 months.
|
Safety will be assessed by evaluating clinically significant changes from Baseline ECGs change in QRS interval.
|
From day 1 through the end of study follow up, an average of 15 months.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Concentration of Lotilaner in Whole Blood
Zeitfenster: From dose through study completion, an average of 15 months.
|
Concentration of lotilaner in whole blood at specified timepoints measured using validated bioanalytical assays.
|
From dose through study completion, an average of 15 months.
|
|
Terminal Elimination Half Life (t½) of Lotilaner
Zeitfenster: At protocol specified timepoints through end study treatment phase, an average of 28 weeks.
|
Terminal elimination half life (t½) of lotilaner.
|
At protocol specified timepoints through end study treatment phase, an average of 28 weeks.
|
|
Area Under the Concentration Time Curve (AUC) of Lotilaner
Zeitfenster: At protocol specified timepoints through end of pharmacokinetic sampling, an average of 15 months.
|
Area under the concentration time curve (AUC) of lotilaner.
|
At protocol specified timepoints through end of pharmacokinetic sampling, an average of 15 months.
|
|
Maximum Observed Concentration (Cmax) of Lotilaner
Zeitfenster: At protocol specified timepoints through end of pharmacokinetic sampling, an average of 15 months.
|
Maximum observed concentration (Cmax) of lotilaner.
|
At protocol specified timepoints through end of pharmacokinetic sampling, an average of 15 months.
|
|
Time to Maximum Observed Concentration (Tmax) of Lotilaner
Zeitfenster: At protocol specified timepoints through end of pharmacokinetic sampling, an average of 15 months.
|
Time to maximum observed concentration (Tmax) of lotilaner.
|
At protocol specified timepoints through end of pharmacokinetic sampling, an average of 15 months.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Gesunde Freiwillige
- Randomisierte, kontrollierte Studie
- Gramnegative bakterielle Infektionen
- Bakterielle Infektionen
- Lyme
- Borrelien
- Lyme-Borreliose
- Infektionen
- Prophylaxe
- Lyme-Borreliose
- Bakterielle Infektionen und Mykosen
- Durch Zecken übertragene Krankheiten
- Borrelien-Infektionen
- Preventative Therapeutic
- Spirochaetales Infections
- Vector Borne Diseases
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- TRS-018
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .